During the last session, Seres Therapeutics Inc (NASDAQ:MCRB)’s traded shares were 0.71 million, with the beta value of the company hitting 2.52. At the end of the trading day, the stock’s price was $0.72, reflecting an intraday loss of -4.53% or -$0.04. The 52-week high for the MCRB share is $1.53, that puts it down -112.5 from that peak though still a striking 25.0% gain since the share price plummeted to a 52-week low of $0.54. The company’s market capitalization is $125.72M, and the average intraday trading volume over the past 10 days was 0.83 million shares, and the average trade volume was 1.34 million shares over the past three months.
Seres Therapeutics Inc (MCRB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.43. MCRB has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.08.
Seres Therapeutics Inc (NASDAQ:MCRB) trade information
Seres Therapeutics Inc (MCRB) registered a -4.53% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -4.53% in intraday trading to $0.72, hitting a weekly high. The stock’s 5-day price performance is 1.36%, and it has moved by -0.57% in 30 days. Based on these gigs, the overall price performance for the year is -4.12%. The short interest in Seres Therapeutics Inc (NASDAQ:MCRB) is 16.72 million shares and it means that shorts have 20.8 day(s) to cover.
The consensus price target of analysts on Wall Street is $1.25, which implies an increase of 42.4% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1.25 and $1.25 respectively. As a result, MCRB is trading at a discount of -73.61% off the target high and -73.61% off the low.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 20M as predicted by 5 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 5M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 5.33%.
MCRB Dividends
Seres Therapeutics Inc is due to release its next quarterly earnings on 2025-Mar-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Seres Therapeutics Inc (NASDAQ:MCRB)’s Major holders
Seres Therapeutics Inc insiders own 13.02% of total outstanding shares while institutional holders control 36.18%, with the float percentage being 41.60%. FLAGSHIP PIONEERING INC. is the largest shareholder of the company, while 80.0 institutions own stock in it. As of 2024-06-30, the company held over 23.12 million shares (or 15.2573% of all shares), a total value of $16.73 million in shares.
The next largest institutional holding, with 22.72 million shares, is of FMR LLC’s that is approximately 14.9934% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $16.44 million.
Also, the Mutual Funds coming in first place with the largest holdings of Seres Therapeutics Inc (MCRB) shares are Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . Data provided on Jan 31, 2025 indicates that Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund owns about 6.79 shares. This amounts to just over 3.90 percent of the company’s overall shares, with a $4.9 million market value. The same data shows that the other fund manager holds slightly less at 3.86, or about 2.21% of the stock, which is worth about $2.78 million.
